Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Cardiac Glycosides Induce Immunogenic Changes in Myeloma Cells and Enhance the Efficacy of Monoclonal and Bispecific Antibody Therapy

Tomoyuki Nakamura, Masaki Ri, Toru Ebina, Yoshiaki Marumo, Yoshiko Oshima, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Takaomi Sanda, Hirokazu Komatsu, Yasumichi Inoue, Hidetoshi Hayashi, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 6813.

https://doi.org/10.1182/blood-2024-200981

Published: 2024

Journal Articles

Genetic Alterations in Primary and Secondary Plasma Cell Leukemia: A Comparative Study Involving Patients with Non-PCL Myeloma

Yoko Nakanishi, Tomotaka Suzuki, Takashi Kanamori, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomoko Narita, Takaomi Sanda, Masaki Ri, Hirokazu Komatsu, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 6842.

https://doi.org/10.1182/blood-2024-200672

Published: 2024

Journal Articles

Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma

Toru Ebina, Masaki Ri, Yoshiko Oshima, Tomoyuki Nakamura, Yoshiaki Marumo, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Hirokazu Komatsu, Hirotake Sakuraba, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 4638.

https://doi.org/10.1182/blood-2024-199941

Published: 2024

Journal Articles

Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

Yoshiaki Marumo, Masaki Ri, Toru Ebina, Tomoyuki Nakamura, Hirokazu Sasaki, Shiori Kinoshita, Tomoko Narita, Tomotaka Suzuki, Takaomi Sanda, Takanori Nanri, Hirokazu Komatsu, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 2411.6.

https://doi.org/10.1182/blood-2024-200675

Published: 2024

Journal Articles

The Impact of MYD88 and/or CD79B Gene Mutations on Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma

Tomotaka Suzuki, Keiichiro Fujii, Naohiro Matsunaga, Hirokazu Sasaki, Takashi Kanamori, Arisa Asano, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Masaki Ri, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki

Blood (2024) 144 (Supplement 1): 3075.

https://doi.org/10.1182/blood-2024-198325

Published: 2024

Journal Articles

Stratifying ‘frail’ Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes

Yukiyasu Kato, Tomotaka Suzuki, Aki Kondo, Naohiro Matsunaga, Takaki Kikuchi, Takashi Kanamori, Takashi Yoshida, Satoshi Kayukawa, Yu Asao, Hiroki Yano, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomoko Narita, Takaomi Sanda, Masaki Ri, Hirokazu Komatsu, Shinsuke Iida

Blood (2024) 144 (Supplement 1): 3342.

https://doi.org/10.1182/blood-2024-201310

Published: 2024

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Journal Articles

Whole Exome Sequencing Analysis of Diffuse Large B-Cell Lymphoma That Progressed to Central Nervous System

Tomotaka Suzuki, Rui Yokomori, Takaomi Sanda, Hiroki Yano, Takaki Kikuchi, Takashi Kanamori, Atsushi Inagaki, Takashi Yoshida, Satoshi Kayukawa, Yoshiko Oshima, Hirokazu Sasaki, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Hiroshi Inagaki, Shinsuke Iida

Blood (2023) 142 (Supplement 1): 1632.

https://doi.org/10.1182/blood-2023-174341

Published: 2023

Journal Articles

Thrombocytopenia and Low CD4/CD8 Ratio at Apheresis Along with Prior Bendamustine Use Increase Risk of CAR-T Cell Manufacturing Failure

Tomoyasu Jo, Yasuyuki Arai, Satoshi Yoshihara, Minoru Kojima, Junko Ikemoto, Tomoe Uemura, Keita Iwaki, Noboru Yonetani, Shin-ichiro Fujiwara, Masaki Ri, Kaoru Kahata, Tokiko Nagamura-Inoue, Minami Yamada-Fujiwara, Ryuji Tanosaki

Blood (2022) 140 (Supplement 1): 1608–1609.

https://doi.org/10.1182/blood-2022-165613

Published: 2022

Journal Articles

Circulating miRNA Profiling of Plasma Samples from Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study to Predict the Response and Toxicity of Bortezomib-Containing Regimen: An Ancillary Study of JCOG1105 (JCOG1105A1)

Masaki Ri, Shimon Nakashima, Miki Nakajima, Shinsuke Iida, Dai Maruyama, Satoshi Osaga, Kensei Tobinai, Noriko Fukuhara, Kana Miyazaki, Norifumi Tsukamoto, Hideki Tsujimura, Makoto Yoshimitsu, Kenichi Miyamoto, Kunihiro Tsukasaki, Hirokazu Nagai

Blood (2022) 140 (Supplement 1): 12647–12649.

https://doi.org/10.1182/blood-2022-156875

Published: 2022

Journal Articles

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Takahiko Murayama, PhD, Kota Sato, MD PhD, Junichi Yamamoto, PhD, Takumi Ito, PhD, Muneyoshi Futami, MD PhD, Masaki Ri, Hiroshi Yasui, MD PhD, Noriko Gotoh, MD, Shinsuke Iida, MD PhD, Tadao Ishida, MD PhD, Hiroshi Handa, MD PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 4325.

https://doi.org/10.1182/blood-2019-122662

Published: 2019

Journal Articles

Lipidomic Profiling of Plasma Samples in Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study for Predicting the Response and Toxicities of Melphalan, Prednisolone and Bortezomib (MPB) Regimen : An Ancillary Study of the JCOG1105 (JCOG1105A1)

Masaki Ri, Shinsuke Iida, MD PhD, Dai Maruyama, MD PhD, Kosuke Saito, Yoshiro Saito, Satoshi Osaga, Masahiro Tohkin, Naoki Miyata, Kensei Tobinai, MD PhD, Noriko Fukuhara, MD PhD, Kana Miyazaki, MD PhD, Yosuke Minami, MD PhD, Norifumi Tsukamoto, MD PhD, Hideki Tsujimura, MD PhD, Makoto Yoshimitsu, MD PhD, Kenichi Miyamoto, Kunihiro Tsukasaki, MD PhD, Hirokazu Nagai, MD PhD

Blood (2019) 134 (Supplement_1): 3156.

https://doi.org/10.1182/blood-2019-122218

Published: 2019

Journal Articles

Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma

Blood (2017) 130 (9): 1114–1124.

https://doi.org/10.1182/blood-2016-09-741983

Published: 2017

Includes: Supplemental data

Journal Articles

Aberrantly Expressed APOBEC3B Induces Mutations in Multiple Myeloma

Hiroyuki Yamazaki, MD, Kotaro Shirakawa, MD PhD, Tadahiko Matsumoto, MD, Hiroyuki Matsui, MD, Wataru Maruyama, MD, Masayuki Kobayashi, MD PhD, Keisuke Shindo, MD PhD, Anamaria Daniela Sarca, MD, Masaki Ri, MD PhD, Shinsuke Iida, MD PhD, Akifumi Takaori-Kondo, MD PhD

Blood (2016) 128 (22): 4453.

https://doi.org/10.1182/blood.V128.22.4453.4453

Published: 2016

Journal Articles

The Abnormal Repression of Mir-375 Expression By Overlapping Epigenetic Dysregulations in Myelomas

Shotaro Tatekawa, MD, Yoshiaki Chinen, MD PhD, Yuji Shimura, MD PhD, Yayoi Matsumura-Kimoto, MD, Hisao Nagoshi, MD PhD, Tsutomu Kobayashi, MD PhD, Eri Kawata, MD PhD, Tomoko Narita, MD PhD, Masaki Ri, MD PhD, Hiroshi Handa, MD PhD, Nobuhiko Uoshima, MD PhD, Shinsuke Iida, MD PhD, Junya Kuroda, MD PhD

Blood (2016) 128 (22): 4460.

https://doi.org/10.1182/blood.V128.22.4460.4460

Published: 2016

Journal Articles

Anti-Myeloma Activity of a Syringolin Analog: A Dual 20S Proteasome Inhibitor of Beta 2 and 5 Subunits

Takashi Yoshida, MD, Masaki Ri, MD PhD, Shiori Kinoshita, MD, Tomoko Narita, MD PhD, Haruhito Totani, MD, Reham Ashour, MD, Ayako Masaki, MD PhD, Asahi Ito, MD PhD, Shigeru Kusumoto, MD PhD, Takashi Ishida, MD PhD, Hirokazu Komatsu, MD PhD, Satoshi Ichikawa, Ph, PhD, Shinsuke Iida, MD PhD

Blood (2016) 128 (22): 4473.

https://doi.org/10.1182/blood.V128.22.4473.4473

Published: 2016

Journal Articles

Identification of Circulating Serum microRNAs As Novel Biomarkers Predicting Disease Progression and Sensitivity to Bortezomib Treatment in Multiple Myeloma

Tomoko Narita, MD PhD, Masaki Ri, MD PhD, Shiori Kinoshita, MD, Takashi Yoshida, MD, Haruhito Totani, MD, Reham Ashour, MD, Ayako Masaki, MD PhD, Asahi Ito, MD PhD, Shigeru Kusumoto, MD PhD, Takashi Ishida, MD PhD, Hirokazu Komatsu, MD PhD, Makoto Osabe, PhD, Masahiro Tohkin, PhD, Shinsuke Iida, MD PhD

Blood (2016) 128 (22): 4408.

https://doi.org/10.1182/blood.V128.22.4408.4408

Published: 2016

Journal Articles

3-Phosphoinositide-Dependent Protein Kinase 1 (PDPK1) Is a Pivotal Cell Signaling Mediator in Multiple Myeloma

Yoshiaki Chinen, MD, Junya Kuroda, MD PhD, Yuji Shimura, MD PhD, Hisao Nagoshi, MD PhD, Miki Kiyota, MD PhD, Mio Yamamoto-Sugitani, MD PhD, Shinsuke Mizutani, MD, Natsumi Sakamoto, Masaki Ri, MD PhD, Eri Kawata, MD PhD, Tsutomu Kobayashi, MD PhD, Yosuke Matsumoto, MD PhD, Shigeo Horiike, MD PhD, Shinsuke Iida, Masafumi Taniwaki, MD PhD

Blood (2014) 124 (21): 4728.

https://doi.org/10.1182/blood.V124.21.4728.4728

Published: 2014

Journal Articles

Amylase-Producing Myeloma Cells Reduced Sensitivity to Dexamethasone and Bortezomib.

Shohei Mizuno, MD, Ichiro Hanamura, MD PhD, Akinobu Ota, Karnan Sivasundaram, Tomoko Narita, MD, Masaki Ri, MD PhD, Motonori Mizutani, MD, Mineaki Goto, MD PhD, Mayuko Gotou, MD PhD, Norikazu Tsunekawa, MD PhD, Masato Shikami, MD PhD, Shinsuke Iida, Yoshitaka Hosokawa, MD PhD, Hiroshi Miwa, MD PhD, Ryuzo Ueda, MD PhD, Masakazu Nitta, MD PhD, Akiyoshi Takami, MD PhD

Blood (2014) 124 (21): 5690.

https://doi.org/10.1182/blood.V124.21.5690.5690

Published: 2014

Journal Articles

Chromosomal Translocation (14;16)-Positive Multiple Myeloma Shows Negativity for CD56 Expression and Unfavorable Outcome Even in the Era of Novel Drugs

Blood (2014) 124 (21): 3349.

https://doi.org/10.1182/blood.V124.21.3349.3349

Published: 2014

NARROW

Cardiac Glycosides Induce Immunogenic Changes in Myeloma Cells and Enhance the Efficacy of Monoclonal and Bispecific Antibody Therapy

Genetic Alterations in Primary and Secondary Plasma Cell Leukemia: A Comparative Study Involving Patients with Non-PCL Myeloma

Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma

Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

The Impact of MYD88 and/or CD79B Gene Mutations on Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma

Stratifying ‘frail’ Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Whole Exome Sequencing Analysis of Diffuse Large B-Cell Lymphoma That Progressed to Central Nervous System

Thrombocytopenia and Low CD4/CD8 Ratio at Apheresis Along with Prior Bendamustine Use Increase Risk of CAR-T Cell Manufacturing Failure

Circulating miRNA Profiling of Plasma Samples from Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study to Predict the Response and Toxicity of Bortezomib-Containing Regimen: An Ancillary Study of JCOG1105 (JCOG1105A1)

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Lipidomic Profiling of Plasma Samples in Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study for Predicting the Response and Toxicities of Melphalan, Prednisolone and Bortezomib (MPB) Regimen : An Ancillary Study of the JCOG1105 (JCOG1105A1)

Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma

Aberrantly Expressed APOBEC3B Induces Mutations in Multiple Myeloma

The Abnormal Repression of Mir-375 Expression By Overlapping Epigenetic Dysregulations in Myelomas

Anti-Myeloma Activity of a Syringolin Analog: A Dual 20S Proteasome Inhibitor of Beta 2 and 5 Subunits

Identification of Circulating Serum microRNAs As Novel Biomarkers Predicting Disease Progression and Sensitivity to Bortezomib Treatment in Multiple Myeloma

3-Phosphoinositide-Dependent Protein Kinase 1 (PDPK1) Is a Pivotal Cell Signaling Mediator in Multiple Myeloma

Amylase-Producing Myeloma Cells Reduced Sensitivity to Dexamethasone and Bortezomib.

Chromosomal Translocation (14;16)-Positive Multiple Myeloma Shows Negativity for CD56 Expression and Unfavorable Outcome Even in the Era of Novel Drugs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only